Clinical Trials · NCT06499857
Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- University of Chicago
- Enrollment
- 200
- Start date
- Apr 2025
- Locations
- 2 sites, United States
- Primary endpoint
- Time to first AF event detected by routine outpatient monitoring